Medtronic's Fair Value: DCF Analysis Suggests Undervaluation at Current Price
ByAinvest
Wednesday, Feb 4, 2026 11:57 pm ET1min read
MDT--
Medtronic's recent share price gains of 1.0% over 7 days, 4.6% over 30 days, 6.0% year to date, 14.6% over 1 year, and 30.4% over 3 years have led to a valuation score of 4 out of 6, indicating the stock is undervalued on several metrics. A discounted cash flow analysis suggests Medtronic trades at a 3.8% discount to its intrinsic value of $105.86 per share, implying the stock is fairly valued.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet